|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Thomas E. Polen Jr.||Pres, CEO & Chairman||2,11M||1,72M||1973|
|Mr. Christopher R. Reidy||Chief Admin. Officer||1,4M||S.O.||1957|
|Mr. Samrat S. Khichi||Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel||2,19M||S.O.||1967|
|Mr. Alberto Mas||Exec. VP & Pres of the Medical Segment||1,15M||1,64M||1961|
|Mr. Christopher DelOrefice||Exec. VP & CFO||S.O.||S.O.||1971|
|Mr. Thomas J. Spoerel||VP, Controller & Chief Accounting Officer||S.O.||S.O.||1978|
|Ms. Elizabeth McCombs||Exec. VP & Chief Technology Officer||S.O.||S.O.||1976|
|Jerry Flasz||Exec. VP of Global Services & Chief Information Officer||S.O.||S.O.||S.O.|
|Ms. Kristen Marie Stewart C.F.A., CFA||Sr. VP of Strategy & Investor Relations||S.O.||S.O.||S.O.|
|Michelle Quinn||Sr. VP and Chief Ethics & Compliance Officer||S.O.||S.O.||S.O.|
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
L’ISS Governance QualityScore de Becton, Dickinson and Company en date du 1 juillet 2021 est 9. Les scores principaux sont Audit : 6; Société : 7; Droits des actionnaires : 10; Compensation : 8.